TMT) in Combination with Pembrolizumab for First
Sichuan Kelun-Biotech has published Phase III clinical trial results in The Lancet for its drug sacituzumab tirumotecan (sac-TMT) when combined with pembrolizumab. The study evaluates the treatment's efficacy for patients with PD-L1-positive non-small cell lung cancer.
Why it matters
The publication of Phase III results in a high-impact journal represents a significant milestone in the development of new cancer therapies.
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
The article is a standard corporate press release regarding medical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in